Dealmaking in 2024

The first quarter of 2024 saw 115 agreed research and development partnerships totaling $36 billion. Eight of the top ten ranked by deal value involved technology platforms for developing a broad range of therapeutics, and three included Novartis as it expands its RNA and gene-based programs.

With its custom assay-design capabilities, investment in point-of-care technology, and global infrastructure, Thermo Fisher Scientific is establishing itself as a partner of choice for companies—from startups through to multinationals—looking to develop breakthrough diagnostics and improve health outcomes post-COVID-19.

JCR Pharmaceuticals’ unique brain-shuttling technology opens new treatment opportunities for meeting the needs of patients grappling with CNS diseases.

MimiVax, Inc. is developing immunotherapeutic vaccines and targeted therapies for treating cancers and preventing recurrence. The company’s lead agent, SurVaxM, targets survivin, a cell-survival protein expressed in cancer cells.

Philadelphia’s Aro Biotherapeutics has developed a novel RNA platform that leverages Centyrin proteins to deliver oligonucleotides to muscle and immune cells.

Screening and diagnostics based on the detection of cancer-generated cellular biomarkers.

Cancer Research Horizons (CRH) is harnessing the skills, expertise, and research network of its parent organization to speed-up the discovery and development of transformative oncology drugs, improve patient outcomes, and advance assets for biopharma partners.